Status:
RECRUITING
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
Lead Sponsor:
Zhujiang Hospital
Conditions:
Multiple Myeloma
MGUS
Eligibility:
All Genders
45+ years
Brief Summary
This study aims to investigate the characteristics of the gut microbiota and immune function status in patients with monoclonal gammopathy complicated by infection, and to analyze the correlation betw...
Detailed Description
The intestine is the largest immune organ in the human body, playing a crucial role in regulating host health, maintaining metabolic and immune homeostasis, and preventing pathogen invasion. The gut m...
Eligibility Criteria
Inclusion
- Age 45 years and older; and
- Patients who were monoclonal gammaglobulin negative by MALDI-TOF MS screening;
- No symptoms of infection and normal indicators of infection (whole blood hs-CRP, serum IL-6, PCT);
- Sufficient remaining whole blood, plasma and faecal samples are available, and relevant case information can be provided.
Exclusion
- Those with a previous history of intestinal tumour, irritable bowel syndrome or inflammatory bowel disease or confirmed in hospital; and
- Patients receiving antibiotic therapy in the last month
- Severe systemic diseases including malignant tumours;
- Insufficient remaining sample volume, or the presence of sample failure such as severe haemolysis, lipaemia or jaundice.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06539832
Start Date
May 1 2024
End Date
December 30 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhujiang Hospital of Southern Medical University
Guanzhou, Guangdong, China, 510280